Shanghai Escugen Biotechnology Co., Ltd
Clinical trials sponsored by Shanghai Escugen Biotechnology Co., Ltd, explained in plain language.
-
New antibody weapon targets Hard-to-Treat blood cancers
Disease control CompletedThis early-phase study tested a new antibody drug called ESG206 in 13 adults with advanced B-cell blood cancers (like lymphoma or leukemia) that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the best dose. Researchers also …
Phase: PHASE1 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated May 17, 2026 13:01 UTC
-
New drug shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called ESG401 in 156 people with advanced solid tumors, including breast, lung, and colon cancers, that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Results focused on side ef…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated May 13, 2026 16:03 UTC